Grifols Net Profit Rises 28% in Q3 2026

Grifols, S.A. released its financial results for the third quarter of 2026, highlighting an 8.4% growth in revenue at constant currency and a 27.9% increase in net profit. The company reported that its nine-month free cash flow improved by €110 million year-over-year, while its leverage ratio declined to 3.98x. Management confirmed the company's full-year 2026 financial guidance. The results reflect robust growth in immunoglobulin products, though dynamics in the Chinese albumin market continued to impact performance.